Invasive Hydatidiform Mole

• Invasive hydatidiform mole is a type of gestational trophoblastic neoplasia (GTN) that develops after an abnormal pregnancy.
• It involves the abnormal proliferation of trophoblastic tissue that invades the uterine wall and can spread.
• Symptoms often include persistent vaginal bleeding, pelvic pain, and abnormally high hCG levels after a molar pregnancy.
• Diagnosis relies on clinical signs, imaging, and persistent elevation of human chorionic gonadotropin (hCG).
• Treatment typically involves chemotherapy, with surgical intervention sometimes necessary.

What is Invasive Hydatidiform Mole?

Invasive hydatidiform mole is a form of gestational trophoblastic neoplasia (GTN) that arises from an abnormal pregnancy, specifically a hydatidiform mole. This condition is characterized by the excessive proliferation of trophoblastic tissue (cells that normally form the placenta) that invades the myometrium, the muscular wall of the uterus. While not technically cancer, it possesses malignant potential due to its ability to invade locally and, in some cases, metastasize to distant sites, most commonly the lungs. It is a persistent form of gestational trophoblastic disease (GTD) that requires careful monitoring and treatment.

The causes of invasive hydatidiform mole are directly linked to a preceding molar pregnancy, which is an abnormal fertilization event. After the evacuation of a molar pregnancy, approximately 15-20% of complete moles and 1-5% of partial moles can develop into persistent GTD, including invasive moles. Risk factors include advanced maternal age, a history of previous molar pregnancies, and certain genetic predispositions, though these are less defined than the direct link to a prior mole. According to the American College of Obstetricians and Gynecologists (ACOG), persistent GTD, which includes invasive moles, occurs in about 1 in 1,500 pregnancies in North America.

Signs and Symptoms of Invasive Hydatidiform Mole

The invasive hydatidiform mole symptoms often manifest after the evacuation of a molar pregnancy, making post-molar follow-up critical. The most common symptom is persistent or irregular vaginal bleeding, which may range from light spotting to heavy hemorrhage. This bleeding typically occurs weeks or months after the initial molar evacuation and does not respond to conventional treatments for post-pregnancy bleeding.

Other significant symptoms can include:

• Pelvic pain or pressure: Caused by the expanding tissue within the uterus.
• Uterine enlargement: The uterus may grow larger than expected for the time since the molar evacuation.
• Abnormally high human chorionic gonadotropin (hCG) levels: Persistent elevation or a rise in hCG levels after molar evacuation is a hallmark sign and the primary diagnostic marker.
• Symptoms of hyperthyroidism: In rare cases, very high hCG levels can mimic thyroid-stimulating hormone (TSH), leading to symptoms like rapid heart rate, tremors, and anxiety.
• Symptoms related to metastasis: If the invasive mole spreads, patients might experience respiratory symptoms (cough, shortness of breath, chest pain) if the lungs are affected, or neurological symptoms if it spreads to the brain.

Treatment Options for Invasive Hydatidiform Mole

The primary goal of invasive hydatidiform mole treatment is to eradicate the abnormal trophoblastic tissue and normalize hCG levels, thereby preventing further invasion or metastasis. Treatment strategies are primarily guided by the patient’s risk stratification, which considers factors such as age, prior pregnancy history, interval from the molar pregnancy, initial hCG level, tumor size, and site of metastasis.

For low-risk invasive moles, single-agent chemotherapy is typically the first-line treatment. Methotrexate or dactinomycin are commonly used agents, administered in cycles until hCG levels return to normal and remain undetectable for several weeks. Patients are closely monitored with serial hCG measurements throughout and after treatment. For high-risk invasive moles, or those that are resistant to single-agent chemotherapy, multi-agent chemotherapy regimens are employed. These often involve a combination of drugs such as etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA/CO regimen). In some cases, surgical intervention, such as hysterectomy, may be considered, particularly for older patients who have completed childbearing and have localized disease that is resistant to chemotherapy, or in cases of severe hemorrhage. Radiation therapy may be used for brain metastases, if present. Regular follow-up with hCG monitoring is essential for all patients to detect any recurrence promptly.